compounded semaglutide crackdown news october 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our FDA warns against compounded versions

Leptin resistance is a promising factor for further research due to its ability to produce contradictory levels of leptin and metabolic responses

User friendly design: They are simple to activate and interpret, making them ideal for use by logistics personnel, healthcare providers, and even patients

It combines real-time radiation imaging, spectroscopy, and dose rate measurement in a compact, lightweight device, making it a practical alternative or complement to larger systems like traditional gamma cameras or CZT-SPECT for quick and its the best choice (CZT) in SPECT crystals, on-the-spot assessments

Adverse reactions for the 1.28 mg dose (11.6 mg/vial formulation) of EGRIFTA WR are expected to be similar to those observed with the 2 mg dose (1 mg/vial formulation) of EGRIFTA [see Clinical Pharmacology (12.3)]